The CNS Drug Development Drum Beat is Getting Louder
By Brian Buntz | August 1, 2022 [image courtesy of Pixabay] The late 1980s and the 1990s were something of a gold rush...
Preclinical Rett Syndrome Studies
Rett syndrome is a neurodevelopmental disorder caused by mutations in the X-linked methyl CpG binding protein 2 (Mecp2) gene. Primarily...
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More
By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with...
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna...
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
A phenotypic high-throughput approach to neuropsychiatric drug discovery Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a...
SmartCube® In Vivo AI Platform for Compound Screening
High-Throughput Phenotypic Drug Discovery SmartCube® is a cutting-edge automated testing platform that guides mice through a series of challenges using...
Privacy Policy
This Policy explains how PsychoGenics, Inc. (also referred to as “PGI”, “we” or “our”) collects, holds, uses and discloses information...
PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders
PARAMUS, NEW JERSEY, August 28, 2024 – PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track...
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997 is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using PsychoGenics’ AI-enabled phenotypic screening platforms. PsychoGenics intends to evaluate RO7117997 as a potential treatment for several psychiatric and neurological conditions, starting with sleep and seizure disorders.